Search Results - "Mitsudomi T"

Which biomarker predicts benefit from EGFR-TKI treatment for patients with lung cancer?

Authors: Uramoto, H. Mitsudomi, T.

Source: British Journal of Cancer. 3/26/2007, Vol. 96 Issue 6, p857-863. 7p. 1 Diagram, 1 Chart.

Malignant transformation of an intrathoracic neurofibroma in von Recklinghausen's disease.

Authors: Inoue, M. Mitsudomi, T. Osaki, T. et al.

Source: Scandinavian Cardiovascular Journal. May98, Vol. 32 Issue 3, p173-175. 3p.

Genetic features of pulmonary adenocarcinoma presenting with ground-glass nodules: the differences between nodules with and without growth.

Authors: Kobayashi, Y. Mitsudomi, T. Sakao, Y. et al.

Source: Annals of Oncology. Jan2015, Vol. 26 Issue 1, p156-161. 6p.

S-1 as an option for second-line treatment of NSCLC. Is the 'East Side Story' applicable in the West?

Authors: Hayashi, H. Mitsudomi, T.

Source: Annals of Oncology. Nov2017, Vol. 28 Issue 11, p2627-2629. 3p. 1 Diagram.

Perioperative Durvalumab for Resectable Non-Small-Cell Lung Cancer.

Authors: Heymach, J. V. Harpole, D. Mitsudomi, T. et al.

Source: New England Journal of Medicine. 11/2/2023, Vol. 389 Issue 18, p1672-1684. 13p.

Early and locally advanced non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.

Authors: Zer, A. Ahn, M.-J. Barlesi, F. et al.

Source: Annals of Oncology. Nov2025, Vol. 36 Issue 11, p1245-1262. 18p.

O3–096BIOMARKER ANALYSIS OF WJOG4107 (A RANDOMIZED PHASE II TRIAL OF ADJUVANT CHEMOTHERAPY WITH S-1 VS CDDP + S-1 IN NSCLC).

Authors: Takeda, M. Mitsudomi, T. Nishio, K. et al.

Source: Annals of Oncology. Nov2013 Supplement 9, Vol. 24, pix63-ix63. 1p.

9008 ORAL Randomized Phase III Trial of Adjuvant Chemotherapy With Gemcitabine Compared With Oral Tegafur-uracil (UFT) in Resected, Stage IB-llla Non-small Cell Lung Cancer (WJTOG 0101)

Authors: Mitsudomi, T. Tada, H. Ichinose, Y. et al.

Source: European Journal of Cancer. Sep2011 Supplement 1, Vol. 47, pS594-S594. 1p.

39IN BEYOND EGFR, KRAS, ALK; WHAT ELSE?

Authors: Mitsudomi, T.

Source: Lung Cancer (01695002). Feb2011 Supplement 2, Vol. 71, pS23-S23. 1p.

A phase 3 study of induction treatment with concurrent chemoradiotherapy versus chemotherapy before surgery in patients with pathologically confirmed N2 stage IIIA nonsmall cell lung cancer (WJTOG9903)

Authors: Katakami N Tada H Mitsudomi T et al.

Source: Cancer (0008543X). Dec2012, Vol. 118 Issue 24, p6126-6135. 10p.

Identifying patients with peripheral-type early non-small cell lung cancer (T1N0M0) for whom irradiation of the primary focus alone could lead to successful treatment.

Authors: Fuwa, N. Daimon, T. Mitsudomi, T. et al.

Source: British Journal of Radiology. Oct2008, Vol. 81 Issue 970, p815-820. 6p. 3 Charts, 1 Graph.

Clinical implications of p53 autoantibodies in the sera of patients with non-small-cell lung cancer.

Authors: Mitsudomi, Tetsuya Suzuki, Susumu Mitsudomi, T et al.

Source: JNCI: Journal of the National Cancer Institute. 10/21/98, Vol. 90 Issue 20, p1563-1568. 6p.

Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer.

Authors: Forde, P. M. Spicer, J. Lu, S. et al.

Source: New England Journal of Medicine. 5/26/2022, Vol. 386 Issue 21, p1973-1985. 13p.

ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancer.

Authors: Passaro, A. Leighl, N. Blackhall, F. et al.

Source: Annals of Oncology. May2022, Vol. 33 Issue 5, p466-487. 22p.

Akt kinase-interacting protein1, a novel therapeutic target for lung cancer with EGFR-activating and gatekeeper mutations.

Authors: Yamada, T Takeuchi, S Fujita, N et al.

Source: Oncogene. 9/12/2013, Vol. 32 Issue 37, p4427-4435. 9p.

A randomised phase II trial of preoperative chemotherapy of cisplatin-docetaxel or docetaxel alone for clinical stage IB/II non-small-cell lung cancer results of a Japan Clinical Oncology Group trial (JCOG 0204).

Authors: Kunitoh, H. Kato, H. Tsuboi, M. et al.

Source: British Journal of Cancer. 9/16/2008, Vol. 99 Issue 6, p852-857. 6p. 6 Charts, 2 Graphs.

Identification of a metastasis signature and the DLX4 homeobox protein as a regulator of metastasis by combined transcriptome approach.

Authors: Tomida, S. Yanagisawa, K. Koshikawa, K. et al.

Source: Oncogene. 7/5/2007, Vol. 26 Issue 31, p4600-4608. 9p. 3 Charts, 3 Graphs.

Predictive factors associated with prolonged survival in patients with advanced non-small-cell lung cancer (NSCLC) treated with gefitinib.

Authors: Satouchi, M. Negoro, S. Funada, Y. et al.

Source: British Journal of Cancer. 4/23/2007, Vol. 96 Issue 8, p1191-1196. 6p.

Identification of an epitope from the epithelial cell adhesion molecule eliciting HLA-A*2402-restricted cytotoxic T-lymphocyte responses.

Authors: Tajima, K. Demachi, A. Ito, Y. et al.

Source: Tissue Antigens. Dec2004, Vol. 64 Issue 6, p650-659. 10p.

Dietary factors and lung cancer risk in Japanese: with special reference to fish consumption and adenocarcinomas.

Authors: Takezaki, T Hirose, K Inoue, M et al.

Source: British Journal of Cancer. 5/1/2001, Vol. 84 Issue 9, p1199. 8p.